GlassScriptPhysician profile
Mackenzie L Thomas
NPI 1730855735
$11,428.04
in general payments reported to CMS, 2019-2025
44 companies · $4,359 in 2025
The $4,359 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $207 · 2022: $2,571 · 2023: $1,807 · 2024: $2,484 · 2025: $4,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,522 · Consulting Fee: $915 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,522.24 |
| Consulting Fee | $915.00 |
| Education | $213.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,990.65 | 2021-2025 | |
| Janssen Biotech, INC. | $1,717.49 | 2022-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,289.86 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $674.28 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Regeneron Healthcare Solutions, INC. | $640.09 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $546.55 | 2022-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $402.76 | 2024-2025 | Zenpep |
| Pfizer INC. | $388.91 | 2022-2025 | |
| Genzyme Corporation | $275.36 | 2022-2025 | |
| Celgene Corporation | $254.12 | 2022-2024 | Zeposia |
| Braintree Laboratories, INC. | $245.56 | 2022-2025 | Suflave, Sutab |
| Organon LLC | $217.76 | 2022-2025 | Renflexis, Hadlima |
| Madrigal Pharmaceuticals | $214.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $207.68 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $205.21 | 2023-2025 | Ibsrela |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $203.94 | 2024-2025 | Vegzelma, Zymfentra |
| Janssen Scientific Affairs, LLC | $199.79 | 2022 | |
| Lilly USA, LLC | $180.34 | 2024-2025 | Omvoh |
| Medtronic, INC. | $156.15 | 2022-2023 | Gi Genius |
| Nestle Healthcare Nutrition INC. | $150.46 | 2022-2023 | |
| Gilead Sciences, INC. | $128.50 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $128.34 | 2022-2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $122.12 | 2022 | |
| Intercept Pharmaceuticals, INC. | $117.84 | 2022-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $80.42 | 2023 | Rebyota |
| Evoke Pharma, INC. | $74.77 | 2022-2025 | |
| Daiichi Sankyo INC. | $65.73 | 2022-2024 | Injectafer |
| Phadia US INC. | $63.25 | 2022-2024 | Immunocap |
| Ironwood Pharmaceuticals, INC | $57.56 | 2022-2024 | |
| Amgen INC. | $52.42 | 2022-2023 | Amjevita, Avsola |
| Azurity Pharmaceuticals, INC. | $49.56 | 2025 | Sutab |
| Astrazeneca Pharmaceuticals LP | $45.18 | 2022 | |
| Alnylam Pharmaceuticals INC. | $44.28 | 2023-2024 | Givlaari |
| Novo Nordisk INC | $35.24 | 2024-2025 | Wegovy |
| Fresenius Kabi USA, LLC | $34.96 | 2023-2024 | |
| Baxter Healthcare | $33.76 | 2022 | |
| Redhill Biopharma INC. | $31.47 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $16.63 | 2024 | Iqirvo |
| Mylan Institutional INC. | $15.70 | 2023 | Hulio |
| Endogastric Solutions, INC | $15.00 | 2022-2023 | Esophyx |
| Shield Therapeutics INC | $14.61 | 2023 | Accrufer |
| Amag Pharmaceuticals, INC. | $13.60 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.39 | 2024 | Simlandi |
| Echosens North America, INC. | $12.50 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.